LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
LAVA Therapeutics (NASDAQ: LVTX), a clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's CEO, Stephen Hurly, will present in a fireside chat format on Monday, September 9, 2024, at 3:30 PM ET.
LAVA Therapeutics specializes in developing the proprietary Gammabody® platform of bispecific gamma delta T cell engagers. Investors and interested parties can access a webcast of the presentation through the company's website under the 'Events' tab in the investor relations section. The replay will be available for 90 days after the presentation.
LAVA Therapeutics (NASDAQ: LVTX), un'azienda clinica nel settore dell'immuno-oncologia, ha annunciato la sua partecipazione alla 26a Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. Il CEO dell'azienda, Stephen Hurly, presenterà in formato chat informale lunedì 9 settembre 2024, alle 15:30 ET.
LAVA Therapeutics si specializza nello sviluppo della piattaforma proprietaria Gammabody® di engagers bispecifici delle cellule T gamma delta. Gli investitori e le parti interessate possono accedere a un webcast della presentazione tramite il sito web dell'azienda nella sezione 'Eventi' sotto la rubrica delle relazioni con gli investitori. La registrazione sarà disponibile per 90 giorni dopo la presentazione.
LAVA Therapeutics (NASDAQ: LVTX), una empresa de inmuno-oncología en etapa clínica, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El CEO de la compañía, Stephen Hurly, presentará en un formato de charla informal el lunes 9 de septiembre de 2024, a las 3:30 PM ET.
LAVA Therapeutics se especializa en el desarrollo de la plataforma propietaria Gammabody® de engagers de células T gamma delta bispecíficas. Los inversores y partes interesadas pueden acceder a una retransmisión de la presentación a través del sitio web de la compañía en la sección 'Eventos' de relaciones con inversores. La repetición estará disponible durante 90 días después de la presentación.
LAVA Therapeutics (NASDAQ: LVTX), 임상 단계의 면역 종양학 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 회사의 CEO인 Stephen Hurly는 2024년 9월 9일 월요일, 동부 표준시 기준 오후 3시 30분에 대담 형식으로 발표할 예정입니다.
LAVA Therapeutics는 비특이적 감마 델타 T 세포 결합제를 개발하는 독점 Gammabody® 플랫폼에 특화되어 있습니다. 투자자 및 관심 있는 분들은 회사 웹사이트의 투자자 관계 섹션 '이벤트' 탭을 통해 발표 내용을 웹캐스트로 시청할 수 있습니다. 발표 후 90일 간 다시 청취할 수 있습니다.
LAVA Therapeutics (NASDAQ: LVTX), une entreprise d'immuno-oncologie en phase clinique, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. Le PDG de l'entreprise, Stephen Hurly, présentera sous la forme d'un échange informel le lundi 9 septembre 2024, à 15h30 ET.
LAVA Therapeutics se spécialise dans le développement de la plateforme propriétaire Gammabody® d'engagers de cellules T gamma delta bispécifiques. Les investisseurs et les parties intéressées peuvent accéder à un webinaire de la présentation via le site web de l'entreprise dans l'onglet 'Événements' de la section des relations avec les investisseurs. La rediffusion sera disponible pendant 90 jours après la présentation.
LAVA Therapeutics (NASDAQ: LVTX), ein Unternehmen für Immunonkologie in der klinischen Phase, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Der CEO des Unternehmens, Stephen Hurly, wird am Montag, den 9. September 2024, um 15:30 Uhr ET in einem informellen Gespräch präsentieren.
LAVA Therapeutics hat sich auf die Entwicklung der proprietären Gammabody®-Plattform von bispezifischen gamma delta T-Zell-Engagern spezialisiert. Investoren und interessierte Parteien können die Präsentation über die Unternehmenswebsite im Bereich 'Events' der Investor Relations abrufen. Die Wiederholung wird 90 Tage nach der Präsentation verfügbar sein.
- None.
- None.
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 26th Annual Global Investment Conference.
Presentation Details
Format: Fireside Chat
Date: Monday, September 9, 2024
Time: 3:30 PM ET
A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavatherapeutics.com/news-events/events. The replay will be archived for 90 days following the presentation date.
About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens.
A Phase 1 dose escalation study (NCT05369000) to evaluate the lead program, LAVA-1207, in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in Europe and the United States in a study evaluating monotherapy and with interleukin-2 (IL-2). The Company is expanding the Phase 1 study to include a combination arm with KEYTRUDA®(pembrolizumab) through a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA. The Company licensed PF-08046052 (formerly LAVA-1223) to Pfizer Inc. for clinical development and commercialization. The pipeline also includes several pre-clinical programs.
For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, X, and YouTube.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. LLC, Rahway, NJ, USA
Gammabody® is a registered trademark of LAVA Therapeutics N.V.
CONTACTS
Investor Relations
ir@lavatherapeutics.com
LifeSci Advisors (IR/Media)
Joyce Allaire
Jallaire@lifesciadvisors.com
FAQ
When is LAVA Therapeutics (LVTX) presenting at the H.C. Wainwright Global Investment Conference?
Who will be representing LAVA Therapeutics (LVTX) at the H.C. Wainwright conference?
What is the format of LAVA Therapeutics' (LVTX) presentation at the conference?
How can investors access LAVA Therapeutics' (LVTX) presentation at the H.C. Wainwright conference?
How long will the replay of LAVA Therapeutics' (LVTX) presentation be available?
